PhysIQ Announces Two New Patent Allowances for Artificial Intelligence Analytics in Wearables

PhysIQ AI wearable patents
Image: PhysIQ

PhysIQ, a company dedicated to enabling proactive care delivery models through its highly scalable cloud-based platform for personalized physiology analytics, announced two new patent allowances by the US Patent & Trademark Office on its core analytics in digital medicine. These analytics help power PhysIQ’s machine learning and artificial intelligence approach to providing a platform for clinical markers of health using continuous wearable sensor data.

Read more Total Brain Joins AMA to Study Uses of Heart Rate Variability Data to Reduce Stress and Cardiovascular Incidents

“We’re thrilled to announce two new patent allowances on our core analytics in digital medicine. The expansion of our patent portfolio for artificial intelligence analytics in wearables is truly exciting,” announced PhyIQ.

The physIQ platform is designed to allow health care providers to monitor high-utilization patients post-discharge in the home environment, and for use by clinical scientists in pharmacological and medical device trials to acquire digital biomarkers for efficacy and safety on subjects wearing sensors, reports Business Wire.

The first patent allowance gives PhysIQ protection for its ground-breaking approach to using deep neural networks to make estimates of cardiopulmonary functional capacity from wearables. The physIQ deep net architecture does this by analysis of the behavior of raw vital signs from human subjects wearing a multivariate sensor throughout activities of daily living. The subject is required only to wear the sensor and the result is computed passively.

A man sleeping
Image: PhysIQ

In conventional medical practice, functional capacity of a human subject is assessed in-clinic with an involved and expensive procedure such as a Cardiopulmonary Exercise Test (CPET) to measure VO2Max, the maximum volume of oxygen uptake of a person. VO2Max is an excellent measure of fitness as well as the physiology of heart failure (HF), chronic obstructive pulmonary disease (COPD), chemotherapy, and similar conditions or treatments.

“Given the difficulty of administering a conventional CPET,” said Matt Pipke, chief technology officer, physIQ, “a low-tech 6-minute Walk Test (6MWT) is often substituted, but it suffers from notorious inaccuracy. With the newly patented approach, physIQ plans to be able to make reasonably accurate estimates of VO2Max and related parameters daily directly from the sensor data with no special activities or procedures.”

Read more Omron and physIQ Collaborate to Improve Cardiovascular Patient Care

The second patent allowance is part of the large suite of patents issued to physIQ for its personalized physiology modeling technology. This technology, for which physIQ received FDA 510(k) clearance in 2015, learns the unique physiology of each human subject from their own sensor data and can then provide a sensitive dynamic baseline for the detection of early signs of change in the behavior of monitored vital signs. Such change can provide warning of compensatory physiological behavior in patients with chronic disease before the patient decompensates into an acute care episode requiring emergency hospitalization. Such early warning can be instrumental for clinicians to reach out to patients at home and take steps to prevent the hospitalization. The approach can also be used in clinical trials to strengthen the signal-to-noise ratio for pharmacological or device efficacy evaluations in support of claims for overall change in health and function.

Previous articleItalgas Deploys RealWear’s HMT-1Z1 Wearable Solution Running OverIT Field Services Management Software
Next articleAbbott-Insulet Collaboration to Combine Abbott’s CGM with Insulet’s Omnipod Horizon Automated Insulin Delivery System
Sam Draper
Sam Draper () is Online Editor at WT | Wearable Technologies specialized in the field of sports and fitness but also passionated about any new lifestyle gadget on the market. Sam can be contacted at press(at)